Active	Status	Sponsor type	Region	Phase	Filter
22 Active 14 Inactive 36 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Meyer, Christian
OCEAN, NCT02168829 / 2016-002353-38: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial	Active, not recruiting	4	1284	Europe, Canada, RoW	Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA	Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc	Atrial Fibrillation, Stroke	07/25	08/25
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas	Recruiting	3	333	Europe, Canada, US	INT230-6, Eribulin, Trabectedin, Pazopanib	Intensity Therapeutics, Inc., Premier Research Group plc	Sarcoma,Soft Tissue	12/27	12/28
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD	Completed	3	806	Europe, Canada, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD DEVELOPMENT, LP	Pulmonary Disease, Chronic Obstructive	08/24	08/24
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)	Terminated	2/3	359	Europe, Canada, US, RoW	Unesbulin, PTC596, Dacarbazine, DTIC, Placebo	PTC Therapeutics, PTC Therapeutics, Inc.	Leiomyosarcoma	06/24	07/24
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors	Active, not recruiting	2	348	Europe, Canada, US	tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin	Seagen, a wholly owned subsidiary of Pfizer, Genmab, Merck Sharp & Dohme LLC	Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck	09/25	08/26
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma	Recruiting	2	201	Europe, US, RoW	INBRX-109, Placebo	Inhibrx Biosciences, Inc	Conventional Chondrosarcoma	09/25	12/26
PTC596-ONC-007-LMS, NCT03761095: A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)	Completed	1	41	US	Unesbulin, PTC596, Dacarbazine, DTIC	PTC Therapeutics	Leiomyosarcoma	02/24	02/24
Wiese, Lothar
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2	Completed	3	4205	Europe, US	ABNCoV2, Comirnaty	Bavarian Nordic	COVID-19 Disease	03/23	10/23
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older	Completed	3	7741	Europe, Canada, US, RoW	Investigational aQIVc, licensed QIVr, licensed aQIV	Seqirus	Influenza, Human	03/24	01/25
fjællegaard, katrine
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Meyer, Christian
OCEAN, NCT02168829 / 2016-002353-38: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial	Active, not recruiting	4	1284	Europe, Canada, RoW	Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA	Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc	Atrial Fibrillation, Stroke	07/25	08/25
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas	Recruiting	3	333	Europe, Canada, US	INT230-6, Eribulin, Trabectedin, Pazopanib	Intensity Therapeutics, Inc., Premier Research Group plc	Sarcoma,Soft Tissue	12/27	12/28
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD	Completed	3	806	Europe, Canada, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD DEVELOPMENT, LP	Pulmonary Disease, Chronic Obstructive	08/24	08/24
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)	Terminated	2/3	359	Europe, Canada, US, RoW	Unesbulin, PTC596, Dacarbazine, DTIC, Placebo	PTC Therapeutics, PTC Therapeutics, Inc.	Leiomyosarcoma	06/24	07/24
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors	Active, not recruiting	2	348	Europe, Canada, US	tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin	Seagen, a wholly owned subsidiary of Pfizer, Genmab, Merck Sharp & Dohme LLC	Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck	09/25	08/26
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma	Recruiting	2	201	Europe, US, RoW	INBRX-109, Placebo	Inhibrx Biosciences, Inc	Conventional Chondrosarcoma	09/25	12/26
PTC596-ONC-007-LMS, NCT03761095: A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)	Completed	1	41	US	Unesbulin, PTC596, Dacarbazine, DTIC	PTC Therapeutics	Leiomyosarcoma	02/24	02/24
Wiese, Lothar
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2	Completed	3	4205	Europe, US	ABNCoV2, Comirnaty	Bavarian Nordic	COVID-19 Disease	03/23	10/23
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older	Completed	3	7741	Europe, Canada, US, RoW	Investigational aQIVc, licensed QIVr, licensed aQIV	Seqirus	Influenza, Human	03/24	01/25
fjællegaard, katrine
No trials found